Topic: Prostate cancer.
Destination: Pfizer launches a virtual training funding grant for healthcare professionals to learn about the evolving paradigm of potential treatment of metastatic castration-resistant prostate cancer (mCRPC) with future PARP inhibitor combinations.
Budget: Maximum 250,000$/proposal
Duration: Not indicated.
Fill out the form below to receive more information: